Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, 45110, Ioannina, Greece.
J Thromb Thrombolysis. 2021 Jul;52(1):111-123. doi: 10.1007/s11239-020-02374-3. Epub 2021 Jan 15.
The current, global situation regarding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and its potentially devastating clinical manifestations, i.e. coronavirus disease 2019 (COVID-19), took the world by storm, as millions of people have been infected worldwide and more than 1,600,000 patients have succumbed. Infection induced by various respiratory viruses may lead to thrombotic complications. Infection-elicited thrombosis may involve a repertoire of distinct, yet interconnected pathophysiological mechanisms, implicating a hyperinflammatory response, platelet activation and triggering of the coagulation cascade. In the present review, we present current knowledge on the pathophysiological mechanisms that may underlie thrombotic complications in SARS-CoV-2 infection. Furthermore, we provide clinical data regarding the incidence rate of thrombotic events in several viral respiratory infections that cause acute respiratory distress syndrome, including SARS-CoV-2 infection and finally we summarize current recommendations concerning thromboprophylaxis and antithrombotic therapy in patients with thrombotic complications related to SARS-CoV-2 infection.
目前,严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)大流行及其潜在破坏性临床表现(即 2019 年冠状病毒病(COVID-19))在全球范围内肆虐,因为全世界已有数百万人感染,超过 160 万人死亡。各种呼吸道病毒感染可导致血栓并发症。感染引起的血栓形成可能涉及一系列不同但相互关联的病理生理机制,涉及过度炎症反应、血小板激活和凝血级联反应的触发。在本综述中,我们介绍了目前关于 SARS-CoV-2 感染中可能导致血栓并发症的病理生理机制的知识。此外,我们还提供了有关几种引起急性呼吸窘迫综合征的病毒性呼吸道感染中血栓事件发生率的临床数据,包括 SARS-CoV-2 感染,最后我们总结了与 SARS-CoV-2 感染相关的血栓并发症患者的血栓预防和抗血栓治疗的当前建议。